La compañía se suma nuevamente a la iniciativa impulsada por la Fundación "la Caixa" en colaboración con Gavi, the Vaccine Alliance. Esta acción solidaria respalda el ODS3 de las Naciones Unidas,...
Read moreThis syndrome is the one that has received the financial donation from Cellers Maset, that through the Pau Massana scholarship collaborates annually with the Parc Taulí Research and Innovation Instit...
Read moreOryzon Genomics announced today that the first patient has been dosed in a Phase I/II trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with immune checkpoint inhibi...
Read moreLa nueva estrategia promovida por la red de agencias reguladoras de la Unión Europea, conocida como EMANS 2028, establece las prioridades para fortalecer la red en un contexto de innovación acelerad...
Read moreThe safety and efficacy of pharmaceutical products largely depend on controlling impurities in their formulations. Therefore, the International Council for Harmonisation of Technical Requirements for ...
Read moreIt has been announced today the successful completion of a €30 million capital increase through the issuance of 12,765,958 new shares, priced at €2.35 per share. This pricing reflects a 15.44%
Read moreEnhanced platform technology and the addition of a robust, high-quality CHO K-1 cell line decreases lead time to Investigational New Drug (IND)
Read moreThis new device has demonstrated its efficacy in the treatment of pain in a study with a photosensitive molecule derived from morphine, one of the most widely used opioids because of its great analges...
Read moreOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today reported financial results for the first quarter ended Marc...
Read moreApTOLL completó un estudio clínico de Fase 1b/2 para el ictus isquémico agudo con resultados positivos. Merck asumirá el desarrollo clínico y la comercialización del fármaco.
Read moreEl medicamento de terapia avanzada HCR045, que se administra a las pacientes, está basado en las células HC016, células madre del tejido adiposo patentadas por Histocell y con una mayor capacidad d...
Read more